急性肾损伤新型生物标志物的研究进展

doi:10.3969/j.issn.1004-583X.2026.05.014

摘要/Abstract

摘要：

急性肾损伤(acute kidney injury, AKI)是住院患者尤其是危重症患者的常见并发症,显著增加病死率、慢性肾脏病发生风险及医疗负担。目前临床诊断仍依赖血肌酐和尿量,敏感度与特异度不足,早期识别面临挑战。本文围绕AKI的新型生物标志物进行综述,分别从反映肾小管上皮细胞损伤与应激、炎症与免疫反应、细胞周期停滞与功能应激、纤维化倾向与远期预后等角度,系统介绍了新型标志物在AKI早期诊断、风险分层和预后评估中的潜在价值及挑战。旨在为临床提供依据,推动AKI的精准管理。

中图分类号:

R692.5

周颖, 周芳芳. 急性肾损伤新型生物标志物的研究进展[J]. 临床荟萃, 2026, 41(5): 475-480.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.05.014

https://www.lchc.cn/CN/Y2026/V41/I5/475

参考文献 45

[1]	Kung CW, Chou YH. Acute kidney disease: An overview of the epidemiology, pathophysiology, and management[J]. Kidney Res Clin Pract, 2023, 42(6): 686-699.doi: 10.23876/j.krcp.23.001.
[2]	Pan HC, Yang SY, Chiou TT, et al. Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: A systematic review and meta-analysis[J]. Crit Care, 2022, 26(1): 349.doi: 10.1186/s13054-022-04223-6.
[3]	Malaeb H, Zilka S, Jarden A, et al. Multicenter evaluation of the pronephro aki^TM assay performance and stability in pediatric patients[J]. Clin Chim Acta, 2025, 578: 120511.doi: 10.1016/j.cca.2025.120511.
[4]	Bufkin KB, Silva J. The xpresscard point-of-care test for human neutrophil gelatinase-associated lipocalin enhances the prediction of acute kidney injury[J]. J Clin Med, 2024, 13(24):7564.doi: 10.3390/jcm13247564.
[5]	Albert C, Haase M, Albert A, et al. Biomarker-guided risk assessment for acute kidney injury: Time for clinical implementation?[J]. Ann Lab Med, 2021, 41(1): 1-15.doi: 10.3343/alm.2021.41.1.1. pmid: 32829575
[6]	Yang X, Chen C, Tian J, et al. Urinary angiotensinogen level predicts aki in acute decompensated heart failure: A prospective, two-stage study[J]. J Am Soc Nephrol, 2015, 26(8): 2032-2041.doi: 10.1681/asn.2014040408. pmid: 25722365
[7]	Akin A, Demir AK, Özmen ZC. Serum and urinary angiotensinogen levels as prognostic indicators in acute kidney injury: A prospective study[J]. Rev Assoc Med Bras, 2023, 69(12): e20230716.doi: 10.1590/1806-9282.20230716.
[8]	Kim KS, Yang HY, Song H, et al. Identification of a sensitive urinary biomarker, selenium-binding protein 1, for early detection of acute kidney injury[J]. J Toxicol Environ Health A, 2017, 80(9): 453-464.doi: 10.1080/15287394.2017.1299655.
[9]	Zhao W, Nikolic-Paterson DJ, Li K, et al. Selenium binding protein 1 protects renal tubular epithelial cells from ferroptosis by upregulating glutathione peroxidase 4[J]. Chem Biol Interact, 2024, 393: 110944.doi: 10.1016/j.cbi.2024.110944.
[10]	Wen Y, Parikh CR. Current concepts and advances in biomarkers of acute kidney injury[J]. Crit Rev Clin Lab Sci, 2021, 58(5): 354-368.doi: 10.1080/10408363.2021.1879000.
[11]	Zhang H, Lang H, Ma M, et al. Decreased preoperative urinary uromodulin as a predictor of acute kidney injury and perioperative kidney dysfunction in patients undergoing cardiac surgery: A prospective cohort study[J]. Clin Chim Acta, 2022, 530: 1-7.doi: 10.1016/j.cca.2022.02.008. pmid: 35176269
[12]	You R, Zheng H, Xu L, et al. Decreased urinary uromodulin is potentially associated with acute kidney injury: A systematic review and meta-analysis[J]. J Intensive Care, 2021, 9(1): 70.doi: 10.1186/s40560-021-00584-2. pmid: 34782019
[13]	Bagshaw SM, Al-Khafaji A, Artigas A, et al. External validation of urinary C-C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury[J]. Crit Care, 2021, 25(1): 185.doi: 10.1186/s13054-021-03618-1.
[14]	Hoste E, Bihorac A, Al-Khafaji A, et al. Identification and validation of biomarkers of persistent acute kidney injury: The ruby study[J]. Intensive Care Med, 2020, 46(5): 943-953.doi: 10.1007/s00134-019-05919-0. pmid: 32025755
[15]	Koyner JL, Chawla LS, Bihorac A, et al. Performance of a standardized clinical assay for urinary C-C motif chemokine ligand 14 (CCL14) for persistent severe acute kidney injury[J]. Kidney360, 2022, 3(7): 1158-1168.doi: 10.34067/kid.0008002021.
[16]	Moledina DG, Obeid W, Smith RN, et al. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis[J]. J Clin Invest, 2023, 133(13):e168950.doi: 10.1172/jci168950.
[17]	Moledina DG, Isguven S, Mcarthur E, et al. Plasma monocyte chemotactic protein-1 is associated with acute kidney injury and death after cardiac operations[J]. Ann Thorac Surg, 2017, 104(2): 613-620.doi: 10.1016/j.athoracsur.2016.11.036. pmid: 28223055
[18]	Peng Y, Wang Q, Jin F, et al. Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients[J]. Ren Fail, 2024, 46(1): 2313171.doi: 10.1080/0886022x.2024.2313171.
[19]	Lee HG, Choi HY, Bae JS. Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease[J]. Kidney Int, 2014, 86(6): 1079-1081.doi: 10.1038/ki.2014.292. pmid: 25427083
[20]	Zhen XW, Song NP, Ma LH, et al. Calprotectin and neutrophil gelatinase-associated lipocalin as biomarkers of acute kidney injury in acute coronary syndrome[J]. Am J Med Sci, 2021, 361(6): 736-743.doi: 10.1016/j.amjms.2020.10.028.
[21]	Yang H, Chen Y, He J, et al. Advances in the diagnosis of early biomarkers for acute kidney injury: A literature review[J]. BMC Nephrol, 2025, 26(1): 115.doi: 10.1186/s12882-025-04040-3. pmid: 40045274
[22]	Schmidt IM, Surapaneni AL, Zhao R, et al. Plasma proteomics of acute tubular injury[J]. Nat Commun, 2024, 15(1): 7368.doi: 10.1038/s41467-024-51304-x. pmid: 39191768
[23]	Pais GM, Avedissian SN, O'donnell JN, et al. Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury[J]. Antimicrob Agents Chemother, 2019, 63(7):e00079-19. doi: 10.1128/aac.00079-19.
[24]	Ibrahim ME, Chang C, Hu Y, et al. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients[J]. Eur J Clin Pharmacol, 2019, 75(1): 51-57.doi: 10.1007/s00228-018-2552-z. pmid: 30220072
[25]	Khorashadi M, Beunders R, Pickkers P, et al. Proenkephalin: A new biomarker for glomerular filtration rate and acute kidney injury[J]. Nephron, 2020, 144(12): 655-661.doi: 10.1159/000509352.
[26]	Donato LJ, Meeusen JW, Lieske JC, et al. Analytical performance of an immunoassay to measure proenkephalin[J]. Clin Biochem, 2018, 58: 72-77.doi: 10.1016/j.clinbiochem.2018.05.010. pmid: 29782819
[27]	Lin LC, Chuan MH, Liu JH, et al. Proenkephalin as a biomarker correlates with acute kidney injury: A systematic review with meta-analysis and trial sequential analysis[J]. Crit Care, 2023, 27(1): 481.doi: 10.1186/s13054-023-04747-5.
[28]	张茜, 赵阳, 崔丽艳. 尿金属蛋白酶组织抑制剂-2与胰岛素样生长因子结合蛋白-7乘积在急性肾损伤的早期诊断、危险分层和预后评估中的研究进展[J]. 中华检验医学杂志, 2021, 44(10): 964-969.doi:10.3760/cma.j.cn114452-20210402-00212.
[29]	Pickkers P, Darmon M, Hoste E, et al. Acute kidney injury in the critically ill: An updated review on pathophysiology and management[J]. Intensive Care Med, 2021, 47(8): 835-850.doi: 10.1007/s00134-021-06454-7. pmid: 34213593
[30]	Jia HM, Cheng L, Weng YB, et al. Cell cycle arrest biomarkers for predicting renal recovery from acute kidney injury: A prospective validation study[J]. Ann Intensive Care, 2022, 12(1): 14.doi: 10.1186/s13613-022-00989-8.
[31]	Oosterom-Eijmael MJP, Hermanns H, Lankadeva YR, et al. Cardiac surgery-associated acute kidney injury[J]. BJA Educ, 2026, 26(2): 92-100.doi: 10.1016/j.bjae.2025.11.001.
[32]	Seibert FS, Heringhaus A, Pagonas N, et al. Dickkopf-3 in the prediction of contrast media induced acute kidney injury[J]. J Nephrol, 2021, 34(3): 821-828.doi: 10.1007/s40620-020-00910-1. pmid: 33275197
[33]	Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: A consensus statement[J]. JAMA Netw Open, 2020, 3(10): e2019209.doi: 10.1001/jamanetworkopen.2020.19209.
[34]	Huo R, Dai M, Fan Y, et al. Predictive value of miRNA-29a and miRNA-10a-5p for 28-day mortality in patients with sepsis-induced acute kidney injury[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2017, 37(5): 646-651.doi: 10.3969/j.issn.1673-4254.2017.05.13.
[35]	Xu L, Li J, Li L, et al. Exploring miR-577 and miR-494-3p as emerging biomarkers in sepsis-associated acute kidney injury: Diagnostic and prognostic perspectives[J]. Microbiol Immunol, 2025, 69(5): 297-306.doi: 10.1111/1348-0421.13210.
[36]	Zou YF, Wen D, Zhao Q, et al. Urinary microRNA-30c-5p and microRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury[J]. Exp Biol Med (Maywood), 2017, 242(6): 657-667.doi: 10.1177/1535370216685005.
[37]	Connor KL, Denby L. MicroRNAs as non-invasive biomarkers of renal disease[J]. Nephrol Dial Transplant, 2021, 36(3): 428-429.doi: 10.1093/ndt/gfz183.
[38]	Clementi A, Virzì GM, Ronco C, et al. Urinary and plasma mirnas in the early detection of acute kidney injury and their possible role as therapeutic targets[J]. J Clin Med, 2025, 14(7):2306.doi: 10.3390/jcm14072306.
[39]	Liang L, Li D, Zeng R, et al. Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: The peacp study[J]. Cardiovasc Diabetol, 2023, 22(1): 92.doi: 10.1186/s12933-023-01831-6. pmid: 37081501
[40]	Chen C, Zhang P, Bao G, et al. Discovery of potential biomarkers in acute kidney injury by ultra-high-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry (uplc-q/tof-ms)[J]. Int Urol Nephrol, 2021, 53(12): 2635-2643.doi: 10.1007/s11255-021-02829-3. pmid: 33686532
[41]	Lee HS, Kim SM, Jang JH, et al. Serum 5-hydroxyindoleacetic acid and ratio of 5-hydroxyindoleacetic acid to serotonin as metabolomics indicators for acute oxidative stress and inflammation in vancomycin-associated acute kidney injury[J]. Antioxidants (Basel), 2021, 10(6):895.doi: 10.3390/antiox10060895.
[42]	Patschan D, Patschan S, Matyukhin I, et al. Metabolomics in acute kidney injury: The clinical perspective[J]. J Clin Med, 2023, 12(12):4083.doi: 10.3390/jcm12124083.
[43]	Ostermann M, Legrand M, Meersch M, et al. Biomarkers in acute kidney injury[J]. Ann Intensive Care, 2024, 14(1): 145.doi: 10.1186/s13613-024-01360-9. pmid: 39279017
[44]	He T, Lin K, Xiong L, et al. Disorder of phospholipid metabolism in the renal cortex and medulla contributes to acute tubular necrosis in mice after cantharidin exposure using integrative lipidomics and spatial metabolomics[J]. J Pharm Anal, 2025, 15(7): 101210.doi: 10.1016/j.jpha.2025.101210.
[45]	Anandakrishnan N, Yi Z, Sun Z, et al. Liquid biopsy-multiomics link adhesion pathway dysregulation to kidney injury severity[J]. Kidney Int Rep, 2025, 10(10): 3592-3610.doi: 10.1016/j.ekir.2025.07.021. pmid: 41141506

急性肾损伤新型生物标志物的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	叶琪, 王莹莹, 邱欣, 陈文科, 操龙斌. 肺炎支原体肺炎合并EB病毒感染患儿血清sST2水平及其与临床指标的相关性[J]. 临床荟萃, 2026, 41(5): 441-446.
[2]	翟琳清, 张浩, 姚灿, 孟雪. IgA血管炎肾炎影响因素及生物标志物的研究进展[J]. 临床荟萃, 2026, 41(5): 468-474.
[3]	刘一坤, 张明, 刘倩, 孙绍婷, 李媛媛, 杜书同. 连续性肾脏替代治疗在脓毒症合并急性肾损伤中的研究进展[J]. 临床荟萃, 2026, 41(4): 374-379.
[4]	李施雨, 赵维纳. 复发缓解型多发性硬化1例并文献学习[J]. 临床荟萃, 2026, 41(3): 249-253.
[5]	河北医科大学第二医院神经外科癫痫亚专业组人工智能诊断模型辅助癫痫脑电图诊断专家共识工作组. 人工智能诊断模型辅助癫痫脑电图诊断专家共识[J]. 临床荟萃, 2026, 41(2): 164-168.
[6]	孙振晓, 张继香. 音乐强迫性障碍1例并文献复习[J]. 临床荟萃, 2026, 41(1): 64-67.
[7]	潘炎, 严晓华, 焦富勇. 川崎病流行病学现状、争议及展望[J]. 临床荟萃, 2025, 40(9): 861-864.
[8]	马良, Severine Martin, 孙广东. 基于加蓬数据的疟疾相关急性肾损伤患者临床特征分析[J]. 临床荟萃, 2025, 40(8): 717-720.
[9]	武媛媛, 孟舰. 代谢重编程在脓毒症相关急性肾损伤中的研究进展[J]. 临床荟萃, 2025, 40(8): 753-757.
[10]	李逍山, 尚攀峰. 肾结核的多模态融合诊断[J]. 临床荟萃, 2025, 40(8): 758-763.
[11]	孙振晓, 于相芬. 皮肤搔抓障碍的研究进展[J]. 临床荟萃, 2025, 40(7): 647-652.
[12]	毛静静, 兰云霞, 陈鲁玉, 宋先荣. A型主动脉夹层合并肠系膜上动脉缺血的研究进展[J]. 临床荟萃, 2025, 40(7): 659-662.
[13]	潘凌峰, 林芳芳, 杨川. 人工智能在前列腺癌超声诊断中的应用[J]. 临床荟萃, 2025, 40(6): 547-552.
[14]	蒲武涛, 肖宜欣, 妥丽, 凯丽比努尔·马木提, 范雪婷, 崇乐. 超声造影诊断肝包虫病的系统评价和meta分析[J]. 临床荟萃, 2025, 40(3): 197-204.
[15]	李忠标, 赵习浩, 杜敏, 王江, 于跃, 张佃良. 肠腔内生性卵巢外腹膜浆液性乳头状腺癌1例并文献复习[J]. 临床荟萃, 2025, 40(3): 257-261.